# ME Therapeutics Extends CD22 Nanobody Option Agreement

> ME Therapeutics extends option to license Canadian nanobody for cancer therapy until February 2027.
- Title: ME Therapeutics Extends CD22 Nanobody Option Agreement
- Summary: ME Therapeutics extends option to license Canadian nanobody for cancer therapy until February 2027. ME Therapeutics extends option agreement to license…
- Keywords: me therapeutics, cd22 nanobody, national research council of canada, car therapy, option agreement, cancer treatment, money, business, Therapeutics, Extends, CD22, Nanobody
- Source: Financialpost — https://financialpost.com/pmn/business-wire-news-releases-pmn/me-therapeutics-extends-option-agreement-for-cd22-nanobody-asset
- Read time: 1 min
- Topics: me therapeutics, cd22 nanobody, national research council of canada, car therapy, option agreement, cancer treatment, money, business
## ME Therapeutics extends option agreement
ME Therapeutics Holdings Inc. extends option to license National Research Council of Canada's CD22 nanobody for CAR therapy.
## Option exercisable until February 10, 2027
The option to license the CD22 binder is now exercisable until february 10 2027.
## Company focuses on in vivo CAR program
ME Therapeutics will continue developing the cd22 nanobody as part of its in vivo car program.
## Publicly listed biotech in Vancouver
ME Therapeutics is a publicly listed biotechnology company based in vancouver focused on developing novel therapeutics.
## CD22 nanobody for cancer treatment
The cd22 nanobody is designed to reprogramme immune cells in vivo to reshape the tumour microenvironment and kill cancer cells.
## Option agreement extension details
All other terms remain the same under the extended option agreement for the cd22 nanobody asset.
## Key takeaway

ME Therapeutics extends option agreement to license National Research Council of Canada's CD22 nanobody for CAR therapy until February 10, 2027.